Breaking: Vertex makes $10B deal for commercial endocrinology biotech Crinetics
Vertex Pharmaceuticals is acquiring commercial endocrinology biotech Crinetics Pharmaceuticals in a $10 billion deal.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals for $10 billion. The transaction represents the largest deal to date for Vertex.
Coverage from Bloomberg, the Wall Street Journal, and STAT emphasizes a broader boom in biotech mergers and acquisitions. Yahoo Finance reports that Crinetics (CRNX) stock rose nearly 100% in after-hours trading following the announcement.
Observers are monitoring the integration of Crinetics' commercial endocrinology focus into Vertex's portfolio as the acquisition proceeds.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 58m ago.
Quick answers
How much is Vertex paying for Crinetics?
The acquisition deal is valued at $10 billion.
How did Crinetics stock react to the news?
According to Yahoo Finance, the stock soared nearly 100% after-hours.
What is Crinetics Pharmaceuticals' area of expertise?
Endpoints News describes Crinetics as a commercial endocrinology biotech.
Coverage (5)
- Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A booms STAT · 10h ago
- Vertex to Buy Crinetics for $10 Billion in Biggest Deal Yet Bloomberg.com · 10h ago
- CRNX Stock Soars Nearly 100% After-Hours On Vertex's $10B Acquisition Yahoo Finance · 10h ago
- Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10 Billion WSJ · 10h ago
- Breaking: Vertex makes $10B deal for commercial endocrinology biotech Crinetics Endpoints News · 10h ago
Topics
Related trends
Private prison company sells two of California’s immigrant detention centers to the feds
The federal government has acquired two privately-owned immigrant detention centers in California from CoreCivic in a $1.5 billion transaction.
Louis Vuitton logo dispute sparks cultural design debate
Tesla Robotaxi Expands To Miami As Slow Rollout Continues. Stock Ticks Up.
Tesla expands its Robotaxi service to Miami, triggering a rise in stock prices despite concerns over scaling.
Blockbuster AI Deal Shows Why Honeywell Had to Break Up
Solstice, a Honeywell spin-off, is pursuing a multi-billion dollar acquisition of Element to target the AI supply chain.
Asian Stocks Set to Gain After Tech-Powered Rally: Markets Wrap
Asian markets experience volatility as a tech-powered rally in AI and memory chips triggers both surges and retreats.